Screening methods of SARS-CoV-2 main protease inhibitors and current applications / 药学学报
Acta Pharmaceutica Sinica
; (12): 1528-1539, 2023.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-978716
Responsible library:
WPRO
ABSTRACT
COVID-19 epidemic continues to spread around the world till these days, and it is urgent to develop more safe and effective new drugs. Due to the limited P3 biosafety laboratories for directly screening inhibitors of virulent viruses with high infectivity, it is necessary to develop rapid and efficient screening methods for viral proteases and other related targets. The main protease (Mpro), which plays a key role in the replication cycle of SARS-CoV-2, is highly conserved and has no homologous proteases in humans, making it an ideal target for drug development. From two different levels, namely, molecular level and cellular level, this paper summarizes the reported screening methods of SARS-CoV-2 Mpro inhibitors through a variety of representative examples, expecting to provide references for further development of SARS-CoV-2 Mpro inhibitors.
Full text:
Available
Health context:
SDG3 - Target 3D Strengthen the capacity for early warning, risk reduction and management of national and global health risks
Health problem:
Biological Hazards
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2023
Document type:
Article